LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will host an investor and analyst R&D forum in London on Wednesday, May 8th from 8:30 a.m. BST to 11:30 a.m. BST.
The event will provide insights into the unmet medical need, the challenges of treating chronic obstructive pulmonary disease (“COPD”) and the payer landscape. Management will present an overview of COPD and of ensifentrine in late-stage clinical development for this indication. The forum will feature a panel of physicians and key opinion leaders in the field of COPD to provide a clinical perspective, as well as a patient living with COPD.
Attendance at this event is by invitation only. For additional details, please contact Victoria Stewart at email@example.com. A live webcast can be accessed on the Investor Relations section of the Verona Pharma website at http://investors.veronapharma.com. A webcast replay will be available for 30 days following the event.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.
For further information, please contact:
|Verona Pharma plc||Tel: +44 (0)20 3283 4200|
|Jan-Anders Karlsson, Chief Executive Officerfirstname.lastname@example.org|
|Victoria Stewart, Director of Communications|
|Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)||Tel: +44 (0) 20 7710 7600|
|Stewart Wallace / Jonathan Senior / Ben Maddison|
|FTI Consulting (UK Media and Investor enquiries)||Tel: +44 (0)20 3727 1000|
|Simon Conway / Natalie Garland-Collinsemail@example.com|
|Westwicke, an ICR Company (US Media and Investor enquiries)|
|Darcie Robinson||Tel: +1 203-919-7905|
|Stephanie Carrington||Tel. +1 646-277-1282|
For further information please contact:
Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200
Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Tel: +44 (0) 203 950 9144
Argot Partners (Investor enquiries)
Tel. +1 646 644 9590